Interferon-α-2b + ribavirin for the treatment of chronic hepatitis c in non-responders to interferon-α-monotherapy

Zeitschrift fur Gastroenterologie

Volumn 38, Issue 2, 2000, Pages 159-164

  Tromm, Andreas ^a   Greving, I ^b   Griga, Th ^b   Mankel, K ^b   Huppe D ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b NONE

Author keywords

Hepatitis C; Interferon; Non responder; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN; RIBAVIRIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEPATITIS C; HUMAN; IMMUNOTHERAPY; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME;

EID: 0034051530     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-14854     Document Type: Article

References (34)

1. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92
2. Poynard T, Marcellin P, Lee SS et al. Randomized trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus of interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32
3. Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alpha interferon alpha relapsers and non-responders: Italian experience. J Hepatol 1995: 23 (suppl. 2): 13-5
4. Bell H, Hellum K, Harthug S et al. Treatment with interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group. Scand J Gastroenterol 1999; 34: 194-8
5. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon-alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-9
6. Torras X, Garcia-Samaniego J, Diago M et al. Treatment of chronic hepatitis C with interferon alpha 2b plus ribavirin (IFN+R) for 24 weeks or 48 weeks in nonresponders and relapsers to a previous course of interferon alone. Preliminary results of a randomised controlled trial. J Hepatol 1999; 30 (suppl. 1): 126
7. Wedemeyer H, Jäckel E, Wedemeyer J et al. Ist eine Kombinationstherapie der chronischen Hepatitis C mit Interferon alpha und Ribavirin bei primären Interferon-Nonrespondern indiziert? - Eine Analyse der eigenen Erfahrungen und eine Zusammenfassung der Literatur. Z Gastroenterol 1998; 36: 819-27
8. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999; 30: 956-61
9. Patterson JL, Fernandez-Larson R. Molecular action of ribavirin. Rev Infect Dis 1990, 12: 1132-46
10. Kahakoo S. Glue P, Grellier L et al. Ribavirin and interferon alpha-2b in chronic hepatitis C: Assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998; 46: 563-70
11. Schalm SW, Hansen BE, Chemello L et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997; 26: 961-6
12. Schvarcz R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995; 46: 43-7
13. Bellobuono A, Mondazzi L, Tempini S et al. Ribavirin and interferon-alpha combination therapy vs alone in the retreatment of chronic hepatitis C: A randomized clinical trial. J Viral Hepat 1997; 4: 185-91
14. Scotto G, Fazio V, Tantimonaco G. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone, Ital J Gastroenterol 1996; 28: 505-11
15. Salmeron J, Perez-Ruiz M, Ruiz-Extremera A et al. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: A randomized trial (Abstract), Hepatology 1996: 24 (suppl. 1): 357A
16. Andreone P, Cursaro C, Gramenzi A et al. IFN alpha-n3 vs IFN alph-n3 plus ribavirin in chronic hepatitis C resistant to other IFN alpha treatments: Results of a randomized multicenter trial (Abstract). Hepatology 1997; 26 (suppl. 2): 349A
17. Brillanti S, Foli M, di Tomaso M et al. Response to triple antiviral therapy in interferon non-responders with chronic hepatitis C (Abstract). J Hepatol 1998; 28 (suppl. 1): 114
18. Pol S, Berthelot P, Brecho C. Ribavirin-interferon vs interferon (alpha 2b-IFN) alone in non responders to alpha-IFN in chronic hepatitis C (Abstract). Hepatology 1996: 24 (suppl. 1): 356A
19. Midella M, Santantonio T, Pietromatera G et al. Ribavirin plus IFN vs IFN alone in the treatment of either non-responder or relapser patients with chronic hepatitis C (Abstract). J Hepatol 1997; 26 (suppl. 1): 181
20. Ascione A, de Luca M, Guardascione MA et al. Interferon plus ribavirin vs. interferon alone in HCV chronic liver disease non responder to a prevoius cycle of interferon alone (Abstract). J Hepatol 1998; 28 (suppl. 1): 198
21. Bellobuono A, Tempini S, Mondazzi L et al. Significant improvement of virological response after ribavirin addition to IFN in still viremic patients after the initial month of IFN therapy for chronic hepatitis C (Abstract). J Hepatol 1998; 28 (suppl. 1): 112
22. Barbaro G, Di Lorenzo G, Soldini M et al. Interferon-alpha-2b and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: An Italian multicenter, randomized, controlled, clinical study. Am J Gastroenterol 1998; 93: 2445-51
23. Pol S, Couzigou P, Bourliere M et al. A randomized trial of ribavirin and interferon-α vs. interferon-α alone in patients with chronic hepatitis C who were non-responders to a previous treatment. J Hepatol 1999; 31: 1-7
24. Moreno-Monteagudo JA, Fernandez-Bermeo M, Garcia-Buey L et al. Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapsers to interferon monotherapy. Aliment Phamacol Ther 1998; 12: 717-23
25. Barbaro G, Belloni G, Di Lorenzo G et al. Alpha interleron 2b plus ribavirin in CHC relapser or not responder patients to alpha interferon 2b alone: An Italian multicenter randomized, controlled clinical study. J Hepatol 1999; 30 (suppl. 1): 116
26. Moreno-Monteagudo JA, Garcia-Buey L, Fernandez-Bermejo M et al. Effectiveness of interferon (IFN) plus ribavirin (RBV) in IFN non-responder patients with chronic hepatitis C (CHC). J Hepatol 1999: 30 (suppl. 1): 230
27. Moscarella S, Buzzelli G, Romanelli RG et al. Interferon-alpha (IFNα) + ribavirin (RIBA) therapy for chronic hepatitis C (CHC) patients, non responders (NRs) to IFNα monotherapy. J Hepatol 1999; 30 (suppl. 1): 248
28. Lopez B, Olaso V, Cordoba J et al. Predictors for non-response to treatment with interferon + ribavirin (IFN+R) in patients with chronic hepatitis C (C-HC). J Hepatol 1999: 30 (suppl. 1): 251
29. Olaso V, Lopez B, Cordoba J et al. Therapeutic efficacy of interferon + ribavirin (IFN + R). 6 vs. 12 months, in chronic heaptitis C (CH-C) patients who were non-responders (NR) or relapsers (RR) to a previous treatment with interferon. J Hepatol 1999; 30 (suppl. 1): 136
30. Brouwer JT, Hansen BE, Niesters HG, Schalm SW. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999; 30: 192-8
31. Wedemeyer H, Caselmann WH, Manns MP. Combination therapy of hepatitis C: An important step but not the final goal. J Hepatol 1998; 29: 1010-4
32. Bellobuono A, Tempini S, Mondazzi L, Brasca P, Ideo G. α-interferon and ribavirin combination treatment in chronic hepatitis C unresponsiveness to IFN: Comparison between three different schedules of 12 months therapy. J Hepatol 1999; 30 (suppl. 1): 121
33. Ascione A, De Luca M, Canestrini C et al. Ribavirin plus IFN-2b daily or thrice weekly: Is there any difference between these two treatments in reducing HCV-RNA? A randomized controlled trial. J Hepatol 1999; 30 (suppl. 1): 117
34. Renner EC, Dufour J-F, Reichen J et al. Daily interferon-α (IFN) induction dosing and ribavirin (R) in IFN non-responders (NR) with chronic hepatitis C (CHC): Initial response and tolerability. J Hepatol 1999; 30 (suppl. 1): 128